Loading…
Underlying
Underlying Price
$8.36
Type
Call
Strike
15
Expiration
Dec 18, 2026
DTE
59d
Moneyness
OTM
Intrinsic
$0.00
IBRX 15 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | $0.95 | +1800.00% | 2 | 68 |
| Oct 30, 2026 | 10d | — | — | 0 | 0 |
| Nov 6, 2026 | 17d | $0.25 | +0.00% | 2 | 2 |
| Nov 13, 2026 | 24d | — | — | 0 | 0 |
| Nov 20, 2026 | 31d | $0.15 | -40.00% | 45 | 1,348 |
| Nov 27, 2026 | 38d | $0.35 | +0.00% | 41 | 41 |
| Dec 18, 2026 | 59d | — | — | 0 | 0 |
| Jan 15, 2027 | 87d | $0.62 | -26.19% | 598 | 13,123 |
| Mar 19, 2027 | 150d | $0.95 | -40.63% | 2 | 2,003 |
| Apr 16, 2027 | 178d | $1.10 | -43.59% | 1 | 48 |
| May 21, 2027 | 213d | $2.00 | +14.29% | 115 | 1,179 |
| Aug 20, 2027 | 304d | $1.71 | -24.67% | 33 | 39 |
| Nov 19, 2027 | 395d | $2.75 | -2.83% | 1 | 8 |
| Jan 21, 2028 | 458d | $2.80 | +3.70% | 53 | 7,821 |
| Mar 17, 2028 | 514d | $3.40 | +3.03% | 1 | 250 |
| Jan 19, 2029 | 822d | $3.65 | -8.29% | 2 | 167 |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.